Home Page News Statistics API Review Formulation Monthly Im&Ex report All Information
? ? ?
Keyword:
?E-mail:xuezhe@healthoo.com
?Tel.:86-10-68032463
  Our services:
?China Im\Ex data service
?Service fees of Chinese Vision
?Our service items
Online information introduction
Monthly information
Conference on ...
Information Release...
Internationalization&nbs...
Welcome to Pro...
Healthoo.com Carbap...
APIs Innovation&nbs...
China Import Export Statistics Report In...
API Export Price by ...
Tylosin Bulk Drug Export&...
China Monthly Export Stat...
China Monthly Export Stat...
China Monthly Export Stat...
Your position:www.martinispin720.com >> EN >> Formulation
The Race to Market: Five Potential Blockbuster GLP-1 Therapies in 20242024-02-22
Enveric selects development candidates from EVM301 Series based on potential to minimize or eliminate the hallucinogenic effect of psychedelic-derived compounds2023-12-08
World Health Organization releases guidelines on chronic low back pain2023-12-08
Merck announces positive results from phase 2 KeyVibe-002 trial evaluating coformulation of vibostolimab pembrolizumab in previously treated patients with metastatic NSCLC2023-12-08
Global cell gene therapy market projected to expat 24% CAGR2023-11-15
Gilead Sciences Reports Q3 2023 Financial Results2023-11-10
Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 20232023-11-09
India’s mental healthcare grapples with stigma, inadequate resources & insufficient expertise2023-11-03
The Future of Personalized Medicine2023-11-03
Sanofi Shares Rebound as Company Announces Consumer Health Division Spinoff2023-11-03
Eli Lilly Collaborates with Redwire Corporation to Explore Drug Manufacturing in Space2023-11-03
Novartis Acquires FDA Priority Review Voucher from bluebird bio for $103 Million2023-11-03
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)2023-11-03
Safety warnings to be provided to all patients with each medicine containing valproate they get under new law: MHRA2023-10-13
Novo Nordisk halts phase III FLOW trial of semaglutide early due to strong efficacy2023-10-13
Leqembi Receives Approval in Japan for the Treatment of Alzheimers Disease: A Milestone in Slowing Cognitive Decline2023-10-13
Indias Quest for Pharma Self-Sufficiency: Reducing Dependence on China2023-10-13
ADDRESS THE INDUSTRY’S CONCERN2023-09-20
Hansoh Pharmas Zolbetuximab Receives BLA Acceptance for Gastric Cancer Treatment in China2023-09-01
GlaxoSmithKline Pharmaceuticals Reports 11% Rise in Q1 Profit Driven by Strong Demfor Vaccines2023-08-11
GLP-1 Weight Loss Drugs: A Review of Current Drugs Developments2023-08-11
Hansoh Pharmas Zolbetuximab Receives BLA Acceptance for Gastric Cancer Treatment in China2023-08-11
Betta Pharmaceuticals CFT8919 approved for clinical trials in the United States2023-07-12
Hengrui Pharmaceuticals innovative drug HRS-4357 injection has been approved for clinical use in prostate cancer2023-07-12
Nine key words & hot events in the pharmaceutical industry in 2023 H12023-07-12
Elon Musk takes ketamine for depression parties? The Controversial Use of Ketamine: A Potent Psychedelic Drug2023-07-03
Pimicotinib was approved by EMA Priority Drug Program2023-06-14
Zhaoke Ophthalmology joins forces with Eyedetec Medical2023-06-14
RemeGen ADC drug RC108 combined with PD-1 has been approved for the treatment of solid tumors in phase Ⅰb/Ⅱ clinical trial2023-06-14
Boanbiodulaglutide injection BA5101 completed phase III clinical trial2023-06-08
With annual sales of Times="32".4 billion, the race is on for the first copy of this innovative drug2023-06-08
The legendary Bio-Citagiorencel reduces the risk of disease progression or death by 74%2023-06-08
1495個 頁次:1/4732個/頁 首頁 上一頁 下一頁 尾頁 轉到:
Our Advantages of Reports
①All reports written by ourselves
②All data having original sources
③Information is the latest
④Continuous historical data
⑤Objective analysis and remark
Purchase Flow of Reports
①Confirm purchase (If necessary sign the contract)
②Transfer payment to company's bank account
③After accepting payment we email the report to clients (PDF format)
④Send the invoice
Bank account
①Beneficiary's Name:Beijing orientbit technology ltd
②Beneficiary's Account No.:110060239018002127366
③Name of bank:Bank of Communications Beijing Branch,Fuwai Sub-Branch
④Address of bank:NO7,FUWAISTREET,XICHENG DISTRICT,BEIJING,CHINA SWIFT CODE:COMMCNSHBJG
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
外国a级黄色大片